Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 225

Results For "WHO"

2595 News Found

Gastrointestinal disorders increasing in India
Public Health | November 25, 2021

Gastrointestinal disorders increasing in India

It is estimated that one-third of our country’s population has some form of these disorders


ADB approves US $ 1.5 bn for Covid-19 vaccines in India
News | November 25, 2021

ADB approves US $ 1.5 bn for Covid-19 vaccines in India

The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people


Medical devices industry needs reforms:  Mehernosh Daruwalla, Founder & MD, Lotus Surgicals
interviews | November 24, 2021

Medical devices industry needs reforms: Mehernosh Daruwalla, Founder & MD, Lotus Surgicals

The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector


Arrowhead Pharmaceuticals enters agreement with GSK to develop NASH drug candidate
Biotech | November 24, 2021

Arrowhead Pharmaceuticals enters agreement with GSK to develop NASH drug candidate

Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales


U.S. FDA approves first treatment for drug-resistant post-transplant infection
Drug Approval | November 24, 2021

U.S. FDA approves first treatment for drug-resistant post-transplant infection

The approval is for Cytomegalovirus, a type of Herpes virus


Fortis Escorts Faridabad introduces Cryo technique to treat lung cancer
Hospitals | November 24, 2021

Fortis Escorts Faridabad introduces Cryo technique to treat lung cancer

Cryo-technology helps in early diagnosis and palliative care in later stages of cancer


Obseva announces U.S. FDA acceptance of new drug application for linzagolix
Biotech | November 23, 2021

Obseva announces U.S. FDA acceptance of new drug application for linzagolix

Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU


Boehringer Ingelheim gets CDSCO nod for Jardiance
Drug Approval | November 23, 2021

Boehringer Ingelheim gets CDSCO nod for Jardiance

Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease


Zydus Cadila submits NDA to Drug Controller General of India for Chronic Kidney Disease
Biotech | November 23, 2021

Zydus Cadila submits NDA to Drug Controller General of India for Chronic Kidney Disease

The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis


Alembic receives tentative U.S. FDA approval for Dabigatran Etexilate capsules
Drug Approval | November 23, 2021

Alembic receives tentative U.S. FDA approval for Dabigatran Etexilate capsules

Dabigatran Etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE)